EUVIMEDEUVIMED entdecken
Crossref

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Kidney Outcomes in Patients with CKD

Mohammad Abdullah Al Zubair Naim, Fridtjof Thomas, Elani Streja, Robert L. Davis, Kamyar Kalantar-Zadeh, Keiichi Sumida, Csaba P. Kovesdy

Journal of the American Society of Nephrology · 2026-10 · 37 (10S)

DOI: 10.1681/asn.2026ref7745h ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, 2026-10. Verfasst von Mohammad Abdullah Al Zubair Naim und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Naim, M. A. A. Z., Thomas, F., Streja, E., Davis, R. L., Kalantar-Zadeh, K., Sumida, K., & Kovesdy, C. P. (2026). Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Kidney Outcomes in Patients with CKD. Journal of the American Society of Nephrology, 37(10S). https://doi.org/10.1681/asn.2026ref7745h

Vancouver

Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Kidney Outcomes in Patients with CKD. Journal of the American Society of Nephrology. 2026;37(10S). doi:10.1681/asn.2026ref7745h

BibTeX
@article{Naim2026,
  author = {Naim, Mohammad Abdullah Al Zubair and Thomas, Fridtjof and Streja, Elani and Davis, Robert L. and Kalantar-Zadeh, Kamyar and Sumida, Keiichi and Kovesdy, Csaba P.},
  title = {Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Kidney Outcomes in Patients with CKD},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  volume = {37},
  number = {10S},
  doi = {10.1681/asn.2026ref7745h}
}
Kostenlos starten →